Any history of HIV- associated encephalopathy
Refractory encephalopathy or ascites
Hepatic encephalopathy within past  months or requirement for medication to prevent or control encephalopathy
No evidence of clinically apparent ascites or active encephalopathy, and/or varices that have not been treated; subjects with controlled ascites or encephalopathy are eligible so long as they meet Childs-Pugh score criterion; please note that controlled ascites and encephalopathy require scores of  each when calculating the C-P score
Evidence of hepatic decompensation including esophageal or gastric variceal bleeding or hepatic encephalopathy
COHORT B, GROUP : HEPATOCELLULAR CARCINOMA: Any episode of hepatic encephalopathy within the previous  months
Presence of symptomatic liver failure including ascites and hepatic encephalopathy
Evidence of portal hypertension with varices, ascites, or hepatic encephalopathy;
Decompensated liver disease as evidenced by clinically significant ascites refractory to diuretic therapy, hepatic encephalopathy, or coagulopathy
Hepatic encephalopathy within past  months or requirement for medications to prevent or control encephalopathy
Evidence of severe portal hypertension with evidence of decompensation either with bleeding varices, large volume ascites, or hepatic encephalopathy
Poorly controlled or refractory (grade -) hepatic encephalopathy
Has had encephalopathy in the last  months; subjects on rifaximin or lactulose to control their encephalopathy are not allowed
Encephalopathy not adequately controlled medically
Patient must not have a diagnosis of hepatic encephalopathy
History of liver decompensation: ascites noted on a physical exam, imaging or other test; variceal bleeding; hepatic encephalopathy
Hepatocellular carcinoma cohort specific exclusion criteria:\r\n* A history of hepatic encephalopathy within the past  months; patients on stable doses of lactulose for prophylaxis or as a result of previous hepatic encephalopathy (more than  months ago) are allowed (for HCC cohort only)\r\n* A history of bleeding esophageal or gastric varices within the last  months prior to initiation of study therapy
Hepatic encephalopathy refractory to medical therapy
History of posterior reversible encephalopathy syndrome
Has had clinically diagnosed hepatic encephalopathy in the last  months.
History of hepatic encephalopathy
Any history of hepatic encephalopathy
Decompensated liver disease as evidenced by clinically significant ascites refractory to diuretic therapy, hepatic encephalopathy, or coagulopathy
Ongoing or recent hepatic encephalopathy
Any history of hepatic encephalopathy
History of posterior reversible encephalopathy syndrome.
Has had encephalopathy in the last  months. Participants on rifaximin or lactulose to control their encephalopathy are not allowed
Presence of hepatic encephalopathy within  weeks of st dose
Decompensated liver disease as evidenced by clinically significant ascites refractory to diuretic therapy, hepatic encephalopathy, or coagulopathy
Hepatic encephalopathy
History of hepatic encephalopathy
Hepatic encephalopathy
Patients with more than % replacement of hepatic parenchyma by tumor or any history of drug related hepatic encephalopathy
Presence of symptomatic liver failure including ascites and hepatic encephalopathy
Hepatic insufficiency resulting in clinical jaundice, encephalopathy and/or variceal bleed within  days prior to study entry
Symptomatic encephalopathy within  months prior to the first dose of TKM- and/or requirement for medication for encephalopathy.
Evidence of encephalopathy within last  months
Active infection, ascites, hepatic encephalopathy
Hepatic encephalopathy, per the investigator's evaluation.
Clinically significant encephalopathy
Patients with a history of chronic active hepatitis, cirrhosis or hepatic encephalopathy
History of or current hepatic encephalopathy or clinically meaningful ascites.
Encephalopathy absent
Clinically detectable hepatic encephalopathy or hepatic encephalopathy requiring medication
Episodes of hepatic encephalopathy within the last  weeks. Patients with prior episodes of hepatic encephalopathy who are clinically stable on lactulose, neomycin, and/or xifaxan therapy are allowed.
